Paragon 28 Reports Third Quarter 2024 Financial Results and Raises 2024 Net Revenue Guidance
Paragon 28, a medical device company in the foot and ankle orthopedic market, reported its Q3 2024 financial results and raised its 2024 net revenue guidance. The company recorded global net revenue of $62.3 million, marking 18.1% reported growth compared to the prior year. U.S. net revenue was $51.2 million, a 14.8% increase, while international net revenue was $11.2 million, up 35.7%. Despite a net loss of $12.3 million, this was an improvement from the $11.2 million loss in Q3 2023. Gross margin decreased to 74.1% from 77.4%. Operating expenses rose 6.3% to $54.6 million. Adjusted EBITDA turned positive to $0.4 million. Free Cash Flow improved by 69.5% year-over-year. The company raised its 2024 net revenue guidance to $252-$256 million, representing 16.5%-18.3% growth.
Paragon 28, un'azienda di dispositivi medici nel mercato ortopedico della caviglia e del piede, ha riportato i risultati finanziari per il terzo trimestre del 2024 e ha innalzato le previsioni di fatturato netto per il 2024. L'azienda ha registrato un fatturato netto globale di 62,3 milioni di dollari, segnando una crescita riportata del 18,1% rispetto all'anno precedente. Il fatturato netto negli Stati Uniti è stato di 51,2 milioni di dollari, un aumento del 14,8%, mentre il fatturato netto internazionale è stato di 11,2 milioni di dollari, in crescita del 35,7%. Nonostante una perdita netta di 12,3 milioni di dollari, si tratta di un miglioramento rispetto alla perdita di 11,2 milioni di dollari nel terzo trimestre del 2023. Il margine lordo è diminuito al 74,1% dal 77,4%. Le spese operative sono aumentate del 6,3% a 54,6 milioni di dollari. L'EBITDA corretto è diventato positivo con 0,4 milioni di dollari. Il flusso di cassa libero è migliorato del 69,5% rispetto all'anno precedente. L'azienda ha innalzato le previsioni di fatturato netto per il 2024 a 252-256 milioni di dollari, corrispondenti a una crescita del 16,5%-18,3%.
Paragon 28, una empresa de dispositivos médicos en el mercado ortopédico del pie y el tobillo, informó sus resultados financieros del tercer trimestre de 2024 y aumentó su guía de ingresos netos para 2024. La compañía registró ingresos netos globales de 62,3 millones de dólares, marcando un crecimiento reportado del 18,1% en comparación con el año anterior. Los ingresos netos en EE. UU. fueron de 51,2 millones de dólares, un aumento del 14,8%, mientras que los ingresos netos internacionales alcanzaron los 11,2 millones de dólares, un incremento del 35,7%. A pesar de una pérdida neta de 12,3 millones de dólares, esto representa una mejora en comparación con la pérdida de 11,2 millones de dólares en el tercer trimestre de 2023. El margen bruto disminuyó al 74,1% desde el 77,4%. Los gastos operativos aumentaron un 6,3% a 54,6 millones de dólares. El EBITDA ajustado se volvió positivo con 0,4 millones de dólares. El flujo de caja libre mejoró en un 69,5% interanual. La compañía elevó su guía de ingresos netos para 2024 a entre 252 y 256 millones de dólares, lo que representa un crecimiento del 16,5%-18,3%.
Paragon 28은 발과 복숭아뼈 정형외과 시장의 의료 기기 회사로, 2024년 3분기 재무 성과를 보고하고 2024년 순수익 가이드를 상향 조정했습니다. 이 회사는 전 세계 순수익으로 6230만 달러를 기록하여 전년 대비 18.1% 성장한 결과를 보였습니다. 미국의 순수익은 5120만 달러로 14.8% 증가했으며, 국제 순수익은 1120만 달러로 35.7% 상승했습니다. 순손실은 1230만 달러로, 2023년 3분기 1120만 달러 손실보다 개선된 수치입니다. 총마진은 77.4%에서 74.1%로 감소했습니다. 운영비용은 6.3% 증가하여 5460만 달러에 달했습니다. 조정된 EBITDA는 40만 달러로 긍정적인 수치를 기록했습니다. 자유 현금 흐름은 전년 대비 69.5% 개선되었습니다. 이 회사는 2024년 순수익 가이드를 2억5200만~2억5600만 달러로 상향 조정했으며, 이는 16.5%-18.3% 성장에 해당합니다.
Paragon 28, une entreprise de dispositifs médicaux dans le marché de l'orthopédie du pied et de la cheville, a annoncé ses résultats financiers du troisième trimestre 2024 et a relevé ses prévisions de chiffre d'affaires net pour 2024. L'entreprise a enregistré un chiffre d'affaires net mondial de 62,3 millions de dollars, marquant une croissance déclarée de 18,1 % par rapport à l'année précédente. Le chiffre d'affaires net aux États-Unis s'élevait à 51,2 millions de dollars, soit une augmentation de 14,8 %, tandis que le chiffre d'affaires net international était de 11,2 millions de dollars, en hausse de 35,7 %. Malgré une perte nette de 12,3 millions de dollars, cela représente une amélioration par rapport à la perte de 11,2 millions de dollars au troisième trimestre 2023. La marge brute est passée de 77,4 % à 74,1 %. Les dépenses d'exploitation ont augmenté de 6,3 % pour atteindre 54,6 millions de dollars. L'EBITDA ajusté est redevenu positif avec 0,4 million de dollars. Le flux de trésorerie libre a amélioré de 69,5 % d'une année sur l'autre. L'entreprise a relevé ses prévisions de chiffre d'affaires net pour 2024 à 252-256 millions de dollars, représentant une croissance de 16,5 % à 18,3 %.
Paragon 28, ein Medizintechnikunternehmen im Bereich der Fuß- und Sprunggelenksorthopädie, hat seine finanziellen Ergebnisse für das dritte Quartal 2024 veröffentlicht und die Prognose für den Nettoumsatz 2024 angehoben. Das Unternehmen verzeichnete globalen Nettoumsatz von 62,3 Millionen USD, was einem reported Wachstum von 18,1% im Vergleich zum Vorjahr entspricht. Der Nettoumsatz in den USA betrug 51,2 Millionen USD, ein Anstieg von 14,8%, während der internationale Nettoumsatz 11,2 Millionen USD betrug, was einem Anstieg von 35,7% entspricht. Trotz eines Nettoverlusts von 12,3 Millionen USD stellt dies eine Verbesserung gegenüber dem Verlust von 11,2 Millionen USD im dritten Quartal 2023 dar. Die Bruttomarge fiel von 77,4% auf 74,1%. Die Betriebskosten stiegen um 6,3% auf 54,6 Millionen USD. Das bereinigte EBITDA wurde positiv mit 0,4 Millionen USD. Der freie Cashflow verbesserte sich um 69,5% im Jahresvergleich. Das Unternehmen hat seine Prognose für den Nettoumsatz 2024 auf 252-256 Millionen USD angehoben, was einem Wachstum von 16,5%-18,3% entspricht.
- Global net revenue of $62.3 million, 18.1% YoY growth.
- U.S. net revenue increased by 14.8%.
- International net revenue rose by 35.7%.
- Adjusted EBITDA turned positive to $0.4 million.
- Free Cash Flow improved by 69.5% year-over-year.
- Raised 2024 net revenue guidance to $252-$256 million, 16.5%-18.3% growth.
- Net loss of $12.3 million, increased from $11.2 million in Q3 2023.
- Gross margin decreased to 74.1% from 77.4%.
- Operating expenses rose by 6.3% to $54.6 million.
Recent Business Updates
-
Recorded global net revenue of
$62.3 million 18.1% and17.6% reported and constant currency growth compared to the prior year period, respectively -
Raised net revenue guidance to
$252 million $256 million 16.5% to18.3% reported growth compared to 2023 - Drove a 969 basis point improvement in operating expense as a percentage of revenue in the third quarter compared to the prior year period and a 500 basis point improvement sequentially compared to the second quarter
- Delivered Adjusted EBITDA(1) profit in the third quarter for the first time since the Company’s October 2021 IPO
-
Improved Free Cash Flow(1) in the third quarter by
69.5% compared to the prior year period and54.7% sequentially compared to the second quarter of 2024 - Launched 13 products year-to-date in high growth and highly strategic end markets
Third Quarter 2024 and Nine Months Ended September 30, 2024 Financial Results
-
Consolidated net revenue for the third quarter of 2024 was
$62.3 million 18.1% and17.6% reported and constant currency growth, respectively, compared to the third quarter of 2023. Consolidated net revenue for the nine months ended September 30, 2023 was$184.4 million 18.4% and18.2% reported and constant currency growth, respectively, compared to the nine months ended September 30, 2023.-
U.S. net revenue for the third quarter of 2024 and nine months ended September 30, 2024 was$51.2 million $151.9 million 14.8% and15.3% reported growth, respectively, compared to the prior year periods. -
International net revenue for the third quarter of 2024 was
$11.2 million 35.7% and32.8% reported and constant currency growth, respectively, compared to the prior year period. International net revenue for the nine months ended September 30, 2024 was$32.5 million 35.3% and34.5% reported and constant currency growth, respectively compared to the prior year period.
-
-
Gross margin was
74.1% for the third quarter of 2024 compared to77.4% in the third quarter of 2023. Gross margin was75.5% for the nine months ended September 30, 2024, compared to78.3% for the nine months ended September 30, 2023. -
Operating expenses were
$54.6 million 6.3% , compared to$51.4 million $173.5 million 12.9% , compared to$153.7 million -
Net loss was
$12.3 million $1.1 million $11.2 million $43.5 million $8.3 million $35.2 million -
Adjusted EBITDA(1) was positive
$0.4 million $3.2 million $2.8 million $10.3 million $0.6 million $10.9 million -
Net cash from operating activities was a use of
$2.7 million $11.4 million $14.1 million $23.9 million $23.6 million $47.5 million -
Free Cash Flow(1) was a use of
$6.3 million $14.4 million $20.7 million $37.0 million $32.4 million $69.4 million -
Cash and total liquidity for the period ended September 30, 2024 were
$39.1 million $89.1 million
------------------------------------------
(1) |
|
Reconciliations of these measures to the corresponding |
“We had a strong third quarter with solid revenue growth performance and meaningful operational improvement,” said Albert DaCosta, Chairman and Chief Executive Officer. “This has been a monumental year for product introductions and we are excited to see our investments in R&D contributing to top-line growth. Paragon 28 is well positioned to continue improving the surgeon experience and foot and ankle patient outcomes.”
“The team has made tremendous headway towards our priorities to be EBITDA positive in 2025 and Free Cash Flow positive in 2026 or sooner,” added Chadi Chahine, Chief Financial Officer and EVP of Supply Chain Operations. “We remain fully committed to delivering on these priorities to position the company for sustainable profitable growth.”
2024 Net Revenue Guidance
The Company is increasing its prior 2024 net revenue guidance, and now expects net revenue to be
The Company’s 2024 net revenue guidance assumes foreign currency translation rates remain consistent with current foreign currency translation rates.
Webcast and Conference Call Information
Paragon 28 will host a conference call to discuss third quarter 2024 financial results on Tuesday, November 12, 2024, at 2:30 p.m. Mountain Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing (833-470-1428) for domestic callers or (404-975-4839) for international callers, using conference ID: 725499. Live audio of the webcast will be available on the “Investors” section of the company’s website at: ir.paragon28.com. The webcast will be archived and available for replay for at least 90 days after the event.
About Paragon 28, Inc.
Based in
Forward Looking Statements
Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: Paragon 28’s potential to shape a better future for foot and ankle patients; statements about the Company’s 2024 net revenue guidance; statements regarding the Company’s priorities to be EBITDA positive in 2025 and Free Cash Flow positive in 2026 or sooner; and the Company’s operational efficiency strategy. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on our current expectations, estimates, and assumptions, valid only as of the date they are made, and subject to risks and uncertainties, some of which we are not currently aware. Forward-looking statements should not be read as a guarantee of future performance or results and may not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. These forward-looking statements are based on Paragon 28’s current expectations and inherently involve significant risks and uncertainties and are subject to numerous risks, including, among other things, risks related to the timely and correct completion of the restatement and restated filings; the risk that additional information may become known prior to the expected filing with the SEC of the restated filings or that other subsequent events may occur that would require the Company to make additional adjustments to its financial statements, which could be material, or delay the filing of the corrected or future periodic reports with the SEC; risks related to the timing and results of the Company’s review of the effectiveness of internal control over financial reporting and related disclosure controls and procedures, remediation of the control deficiencies identified and our ability to implement and maintain effective internal control over financial reporting in the future, which may adversely affect the accuracy and timeliness of our financial reporting; identification of errors in our financial reporting in the future that require us to restate previously issued financial statements, which may subject us to unanticipated costs or regulatory penalties and could cause investors to lose confidence in the accuracy and completeness of our financial statements; factors relating to uncertainties as to any difficulties with respect to the Company's operational efficiency strategy, including expenses associated such strategy; the effect of the announcement of the Company's operational efficiency strategy on the Company's ability to retain and hire key personnel and to maintain relationships with customers, suppliers and other business partners; risks related to the possible diversion of management’s attention as a result of the Company's operational efficiency strategy; uncertainties as to the Company's ability and the amount of time necessary to realize the expected benefits of the Company's operational efficiency strategy; and those set forth under the caption “Risk Factors” in the Company’s most recent filings with the Securities and Exchange Commission. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Paragon 28’s business in general, see Paragon 28’s current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K/A for the fiscal year ended December 31, 2023, as updated periodically with its other filings with the SEC. These forward-looking statements are made as of the date of this press release, and Paragon 28 assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Paragon 28’s net revenue guidance for 2024 is not necessarily indicative of our operating results for any future periods.
Use of Non-GAAP Financial Measures and Their Limitations
In addition to our results and measures of performance determined in accordance with
Adjusted EBITDA is a key performance measure that our management uses to assess our financial performance and is also used for internal planning and forecasting purposes. We define Adjusted EBITDA as earnings (loss) before interest expense, income tax expense (benefit), depreciation and amortization, stock-based compensation expense, employee stock purchase plan expense, non-recurring expenses, and certain other non-cash expenses.
We believe that Adjusted EBITDA, together with a reconciliation to net income, helps identify underlying trends in our business and helps investors make comparisons between our company and other companies that may have different capital structures, tax rates, or different forms of employee compensation. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and future prospects, and allowing for greater transparency with respect to a key financial metric used by our management in its financial and operational decision-making. Our use of Adjusted EBITDA has limitations as an analytical tool, and you should not consider these measures in isolation or as a substitute for analysis of our financial results as reported under
- other companies, including companies in our industry which have similar business arrangements, may report Adjusted EBITDA, or similarly titled measures but calculate them differently, which reduces their usefulness as comparative measures;
- although depreciation and amortization expenses are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and Adjusted EBITDA does not reflect cash capital expenditures for such replacements or for new capital expenditure requirements;
- Adjusted EBITDA also does not reflect changes in, or cash requirements for, our working capital needs or the potentially dilutive impact of stock-based compensation; and
- Adjusted EBITDA does not reflect the interest expense, or the cash requirements necessary to service interest or principal payments on our debt that we may incur.
Free Cash Flow is an additional key performance measure that our management uses to assess our financial performance and liquidity. We define Free Cash Flow as net cash provided by operating activities less capital expenditures. The Company’s capital expenditures include amounts related to purchases of property and equipment. Additionally, management believes Free Cash Flow is helpful in assessing our operational efficiency and the effectiveness of our capital expenditures, and that monitoring Free Cash Flow can help us manage financial risk. In addition, management believes Free Cash Flow provides meaningful incremental information to investors to consider when evaluating the performance of the Company.
Additionally, we report revenue growth on a constant-currency basis in order to facilitate period-to-period comparisons of results without regard to the impact of fluctuating foreign currency exchange rates. The term foreign currency exchange rates refers to the exchange rates used to translate the company’s operating results for all countries where the functional currency is not the
The company believes disclosure of constant-currency revenue growth rates is helpful to investors because it facilitates period-to-period comparisons. However, constant-currency revenue growth rates are non-GAAP financial measures and are not meant to be considered as an alternative or substitute for comparable measures prepared in accordance with GAAP. Constant-currency growth has no standardized meaning prescribed by GAAP and should be read in conjunction with our consolidated financial statements prepared in accordance with GAAP. We calculate constant-currency growth rates by translating local currency amounts in the current period at actual foreign exchange rates for the prior period.
Because of these and other limitations, you should consider our non-GAAP measures only as supplemental to other GAAP-based financial measures.
PARAGON 28, INC. AND SUBSIDIARIES
|
||||||||
|
|
|||||||
|
|
|
|
|
|
|
||
|
|
September 30, 2024 |
|
December 31, 2023 |
||||
ASSETS |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
39,145 |
|
|
$ |
75,639 |
|
Trade receivables, net of allowance for doubtful accounts of |
|
|
35,823 |
|
|
|
37,323 |
|
Inventories, net |
|
|
96,449 |
|
|
|
90,046 |
|
Income taxes receivable |
|
|
1,461 |
|
|
|
794 |
|
Other current assets |
|
|
4,732 |
|
|
|
3,997 |
|
Total current assets |
|
|
177,610 |
|
|
|
207,799 |
|
|
|
|
|
|
|
|
||
Property and equipment, net |
|
|
74,016 |
|
|
|
74,122 |
|
Intangible assets, net |
|
|
20,937 |
|
|
|
21,674 |
|
Goodwill |
|
|
25,465 |
|
|
|
25,465 |
|
Deferred income taxes |
|
|
714 |
|
|
|
705 |
|
Other assets |
|
|
3,266 |
|
|
|
2,918 |
|
Total assets |
|
$ |
302,008 |
|
|
$ |
332,683 |
|
|
|
|
|
|
|
|
||
LIABILITIES & STOCKHOLDERS' EQUITY |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
20,693 |
|
|
$ |
21,696 |
|
Accrued expenses |
|
|
27,424 |
|
|
|
27,781 |
|
Other current liabilities |
|
|
1,336 |
|
|
|
883 |
|
Current maturities of long-term debt |
|
|
640 |
|
|
|
640 |
|
Income taxes payable |
|
|
626 |
|
|
|
243 |
|
Total current liabilities |
|
|
50,719 |
|
|
|
51,243 |
|
|
|
|
|
|
|
|
||
Long-term liabilities: |
|
|
|
|
|
|
||
Long-term debt net, less current maturities |
|
|
109,979 |
|
|
|
109,799 |
|
Other long-term liabilities |
|
|
994 |
|
|
|
1,048 |
|
Deferred income taxes |
|
|
245 |
|
|
|
233 |
|
Income taxes payable |
|
|
638 |
|
|
|
635 |
|
Total liabilities |
|
|
162,575 |
|
|
|
162,958 |
|
|
|
|
|
|
|
|
||
Stockholders' equity: |
|
|
|
|
|
|
||
Common stock, |
|
|
834 |
|
|
|
827 |
|
Additional paid in capital |
|
|
311,342 |
|
|
|
298,394 |
|
Accumulated deficit |
|
|
(167,165 |
) |
|
|
(123,646 |
) |
Accumulated other comprehensive loss |
|
|
404 |
|
|
|
132 |
|
Treasury stock, at cost; 913,519 shares as of September 30, 2024 and December 31, 2023 |
|
|
(5,982 |
) |
|
|
(5,982 |
) |
Total stockholders' equity |
|
|
139,433 |
|
|
|
169,725 |
|
Total liabilities & stockholders' equity |
|
$ |
302,008 |
|
|
$ |
332,683 |
|
PARAGON 28, INC. AND SUBSIDIARIES
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
||||||||||||
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net revenue |
$ |
62,336 |
|
|
$ |
52,783 |
|
|
$ |
184,434 |
|
|
$ |
155,828 |
|
|
Cost of goods sold |
|
16,159 |
|
|
|
11,922 |
|
|
|
45,262 |
|
|
|
33,750 |
|
|
Gross profit |
|
46,177 |
|
|
|
40,861 |
|
|
|
139,172 |
|
|
|
122,078 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|||||
Research and development |
|
5,661 |
|
|
|
7,244 |
|
|
|
20,328 |
|
|
|
21,976 |
|
|
Selling, general, and administrative |
|
48,967 |
|
|
|
44,126 |
|
|
|
153,188 |
|
|
|
131,773 |
|
|
Total operating expenses |
|
54,628 |
|
|
|
51,370 |
|
|
|
173,516 |
|
|
|
153,749 |
|
|
Operating loss |
|
|
(8,451 |
) |
|
|
(10,509 |
) |
|
|
(34,344 |
) |
|
|
(31,671 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other income (expense), net |
|
|
(651 |
) |
|
|
369 |
|
|
|
(4 |
) |
|
|
(323 |
) |
Interest expense, net |
|
|
(3,031 |
) |
|
|
(1,119 |
) |
|
|
(8,570 |
) |
|
|
(3,127 |
) |
Total other expense, net |
|
|
(3,682 |
) |
|
|
(750 |
) |
|
|
(8,574 |
) |
|
|
(3,450 |
) |
Loss before income taxes |
|
|
(12,133 |
) |
|
|
(11,259 |
) |
|
|
(42,918 |
) |
|
|
(35,121 |
) |
Income tax expense (benefit) |
|
|
205 |
|
|
|
(108 |
) |
|
|
601 |
|
|
|
90 |
|
Net loss |
|
$ |
(12,338 |
) |
|
$ |
(11,151 |
) |
|
$ |
(43,519 |
) |
|
$ |
(35,211 |
) |
Foreign currency translation adjustment |
|
1,117 |
|
|
|
(630 |
) |
|
|
272 |
|
|
|
(1,012 |
) |
|
Comprehensive loss |
$ |
(11,221 |
) |
|
$ |
(11,781 |
) |
|
$ |
(43,247 |
) |
|
$ |
(36,223 |
) |
|
Weighted average number of shares of common stock outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic |
|
|
83,560,337 |
|
|
|
82,548,892 |
|
|
|
83,178,600 |
|
|
|
81,878,814 |
|
Diluted |
|
|
83,560,337 |
|
|
|
82,548,892 |
|
|
|
83,178,600 |
|
|
|
81,878,814 |
|
Net loss per share attributable to common stockholders: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic |
|
$ |
(0.15 |
) |
|
$ |
(0.14 |
) |
|
$ |
(0.52 |
) |
|
$ |
(0.43 |
) |
Diluted |
|
$ |
(0.15 |
) |
|
$ |
(0.14 |
) |
|
$ |
(0.52 |
) |
|
$ |
(0.43 |
) |
PARAGON 28, INC. AND SUBSIDIARIES
|
||||||||
|
|
|
|
|
|
|
||
|
|
Nine Months Ended September 30, |
||||||
|
|
2024 |
|
|
2023 |
|||
Cash flows from operating activities |
|
|
|
|
|
|
||
Net loss |
|
$ |
(43,519 |
) |
|
$ |
(35,211 |
) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
||
Depreciation and amortization |
|
|
13,573 |
|
|
|
10,602 |
|
Allowance for doubtful accounts |
|
|
721 |
|
|
|
147 |
|
Provision for excess and obsolete inventories |
|
|
8,753 |
|
|
|
3,204 |
|
Stock-based compensation |
|
|
9,537 |
|
|
|
10,294 |
|
Change in fair value of financial instruments |
|
|
(267 |
) |
|
|
(57 |
) |
Other |
|
|
910 |
|
|
|
(34 |
) |
Changes in other assets and liabilities, net of acquisitions: |
|
|
|
|
|
|
||
Accounts receivable |
|
|
1,156 |
|
|
|
3,706 |
|
Inventories |
|
|
(14,586 |
) |
|
|
(31,117 |
) |
Accounts payable |
|
|
(1,013 |
) |
|
|
12,468 |
|
Accrued expenses |
|
|
1,522 |
|
|
|
3,718 |
|
Accrued legal settlement |
|
|
— |
|
|
|
(22,000 |
) |
Income tax receivable/payable |
|
|
(215 |
) |
|
|
(533 |
) |
Other assets and liabilities |
|
|
(441 |
) |
|
|
(2,704 |
) |
Net cash used in operating activities |
|
|
(23,869 |
) |
|
|
(47,517 |
) |
|
|
|
|
|
|
|
||
Cash flows from investing activities |
|
|
|
|
|
|
||
Purchases of property and equipment |
|
|
(13,119 |
) |
|
|
(21,893 |
) |
Proceeds from sale of property and equipment |
|
|
926 |
|
|
|
795 |
|
Purchases of intangible assets |
|
|
(881 |
) |
|
|
(933 |
) |
Net cash used in investing activities |
|
|
(13,074 |
) |
|
|
(22,031 |
) |
|
|
|
|
|
|
|
||
Cash flows from financing activities |
|
|
|
|
|
|
||
Payments on long-term debt |
|
|
(480 |
) |
|
|
(568 |
) |
Payments of debt issuance costs |
|
|
(18 |
) |
|
|
— |
|
Proceeds from issuance of common stock, net of issuance costs |
|
|
— |
|
|
|
68,453 |
|
Proceeds from exercise of options |
|
|
3,188 |
|
|
|
2,535 |
|
RSU vesting, taxes paid |
|
|
(423 |
) |
|
|
— |
|
Proceeds from employee stock purchase plan |
|
|
403 |
|
|
|
560 |
|
Payments on earnout liability |
|
|
(2,000 |
) |
|
|
(5,500 |
) |
Net cash provided by financing activities |
|
|
670 |
|
|
|
65,480 |
|
|
|
|
|
|
|
|
||
Effect of exchange rate changes on cash and cash equivalents |
|
|
(221 |
) |
|
|
549 |
|
Net decrease in cash and cash equivalents |
|
|
(36,494 |
) |
|
|
(3,519 |
) |
Cash and cash equivalents at beginning of period |
|
|
75,639 |
|
|
|
38,468 |
|
Cash and cash equivalents at end of period |
|
$ |
39,145 |
|
|
$ |
34,949 |
|
PARAGON 28, INC. AND SUBSIDIARIES
|
||||||||||||||||
The following table provides a reconciliation of Adjusted EBITDA to Net loss for the periods presented: |
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
||||||||||||
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
|
|
|
|
|
|
|
|
|
|
|
||||||
Net loss |
|
$ |
(12,338 |
) |
|
$ |
(11,151 |
) |
|
$ |
(43,519 |
) |
|
$ |
(35,211 |
) |
Interest expense, net |
|
|
3,031 |
|
|
|
1,119 |
|
|
|
8,570 |
|
|
|
3,127 |
|
Income tax expense |
|
|
205 |
|
|
|
(108 |
) |
|
|
601 |
|
|
|
90 |
|
Depreciation and amortization expense |
|
|
4,705 |
|
|
|
4,188 |
|
|
|
13,573 |
|
|
|
10,602 |
|
Stock based compensation expense |
|
|
3,425 |
|
|
|
3,512 |
|
|
|
9,537 |
|
|
|
10,294 |
|
Employee stock purchase plan expense |
|
|
84 |
|
|
|
86 |
|
|
|
252 |
|
|
|
268 |
|
Change in fair value of financial instruments(1) |
|
|
334 |
|
|
|
(423 |
) |
|
|
(267 |
) |
|
|
(57 |
) |
Workforce optimization - severance(2) |
|
|
986 |
|
|
|
— |
|
|
|
986 |
|
|
|
— |
|
Adjusted EBITDA |
|
$ |
432 |
|
|
$ |
(2,777 |
) |
|
$ |
(10,267 |
) |
|
$ |
(10,887 |
) |
-----------------------------------------
| (1) |
|
Represents the non-cash change in fair value of our interest rate swap contract and earnout liability for all periods presented. |
(2) |
|
Represents severance costs incurred pursuant to an ongoing operational efficiency strategy. |
The following table provides a reconciliation of Free Cash Flow to Net cash used in operating activities for the periods presented: |
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net cash used in operating activities |
|
$ |
(2,665 |
) |
|
$ |
(14,114 |
) |
|
$ |
(23,869 |
) |
|
$ |
(47,517 |
) |
Purchases of property and equipment |
|
|
(3,628 |
) |
|
|
(6,539 |
) |
|
|
(13,119 |
) |
|
|
(21,893 |
) |
Free Cash Flow |
|
$ |
(6,293 |
) |
|
$ |
(20,653 |
) |
|
$ |
(36,988 |
) |
|
$ |
(69,410 |
|
PARAGON 28, INC. AND SUBSIDIARIES
|
||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Three Months Ended September 30, |
|
Change |
|
Nine Months Ended September 30, |
|
Change |
||||||||||||
|
|
2024 |
|
2023 |
|
% |
|
2024 |
|
2023 |
|
% |
||||||||
Total Consolidated Revenues |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
As Reported |
|
$ |
62,336 |
|
|
$ |
52,783 |
|
18.1 |
% |
|
$ |
184,434 |
|
|
$ |
155,828 |
|
18.4 |
% |
Impact of foreign currency exchange rates |
|
|
(241 |
) |
|
|
— |
|
* |
|
|
(194 |
) |
|
|
— |
|
* |
||
Constant-currency net revenues |
|
$ |
62,095 |
|
|
$ |
52,783 |
|
17.6 |
% |
|
$ |
184,240 |
|
|
$ |
155,828 |
|
18.2 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total International Revenues |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
As Reported |
|
$ |
11,176 |
|
|
$ |
8,235 |
|
35.7 |
% |
|
$ |
32,521 |
|
|
$ |
24,035 |
|
35.3 |
% |
Impact of foreign currency exchange rates |
|
|
(241 |
) |
|
|
— |
|
* |
|
|
(194 |
) |
|
|
— |
|
* |
||
Constant-currency net revenues |
|
$ |
10,935 |
|
|
$ |
8,235 |
|
32.8 |
% |
|
$ |
32,327 |
|
|
$ |
24,035 |
|
34.5 |
% |
--------------------------------------------
| * |
|
Not meaningful |
View source version on businesswire.com: https://www.businesswire.com/news/home/20241112393910/en/
Investor Contact:
Matt Brinckman
Senior Vice President, Strategy and Investor Relations
mbrinckman@paragon28.com
Source: Paragon 28, Inc.
FAQ
What were Paragon 28's Q3 2024 financial results?
How much did Paragon 28's U.S. net revenue grow in Q3 2024?
What is Paragon 28's updated 2024 net revenue guidance?
What was Paragon 28's international net revenue growth in Q3 2024?
What was Paragon 28's gross margin in Q3 2024?
Did Paragon 28 achieve positive Adjusted EBITDA in Q3 2024?
